Blood and Sweat: How Persperion is Taking the Needle Away from Blood Glucose Monitoring

Persperion Test Strip (Image courtesy of Persperion)

Every day, hundreds of millions of people with diabetes face a familiar ritual: a lancet, a drop of blood, and a test strip. It works, but it is painful, inconvenient, and just uncomfortable enough that many people test less often than they should. The search for a truly non-invasive glucose monitor has been underway for decades. Continuous glucose monitors (CGMs) have made real progress, but they are expensive, require subcutaneous insertion, and remain expensive or inaccessible for many people with diabetes who still rely on fingerpricks.

AnalyticalChemistryStartups recently had the opportunity to speak with Lu Yin, co-founder and CEO of Persperion Diagnostics, to learn how their team is taking a fundamentally different route — one that involves no needles. Just a fingertip and thirty seconds.

From Prof. Wang's Lab to the Market

Persperion’s innovation comes from the research group of Professor Joseph Wang at UC San Diego, a leader in non-invasive biosensing and wearable electrochemical devices. Lu Yin completed his PhD in nanoengineering at UCSD, spending years exploring how small molecules present in sweat, saliva, tears, and other biofluids could be used to monitor health. Co-founder Alan Liu (nanoengineering BS, MS in management from Duke) came up through the same lab environment, and the two co-founded Persperion in 2022.

The decision to commercialize wasn't purely academic momentum. Yin is candid about how many promising biosensor papers still leave a substantial gap between laboratory novelty and real-world practicality. "When publishing a paper, you're focused on novelties, less on practicality," he explained. Sweat sensing in particular had accumulated a strong publication record but a weak commercial case: sweat collected from different body locations at the same time shows significant concentration variability, making reliable correlation to blood biomarker levels difficult. And asking someone to exercise on demand — just to collect enough sweat — is not a viable product experience.

Why the Fingertip Changes Everything

The insight that unlocked Persperion's approach is anatomical: the fingertip has a high density of eccrine sweat glands on the human body, roughly an order of magnitude higher than other skin surfaces. It is also why we leave fingerprints on everything we touch. Critically, the capillary blood flow to the fingertips is consistent and well-characterized, which means fingertip sweat biomarker concentrations correlate reliably to blood levels in a way that sweat from other parts of the body does not.

The challenge is volume. Touching a sensor surface for a few seconds yields only tens of nanoliters of sweat—orders of magnitude less than a finger-prick blood sample—and that sweat evaporates quickly. Yin and his team redesigned the geometry of the sensor to maximize uniform contact between the fingertip's sweat film and the strip surface. The result is a small, finger-sized test strip in a pocketable Sweat Glucose Monitor. Pressing a fingertip for approximately 30 seconds is sufficient to collect the sample and complete the electrochemical measurement.

The underlying chemistry is chronoamperometric electrochemical sensing using glucose oxidase, an enzyme that has been central to glucose detection for roughly six decades. The core enzymatic chemistry is well-established, but Persperion’s differentiation lies in how the sensing architecture, coatings, and strip geometry are engineered for ultra-low-volume fingertip sweat samples. Specifically, specially engineered coatings provide selectivity while preserving sufficient pathways for rapid sweat permeation. 

This is where the comparison to CGMs is instructive: a typical CGM sensor is coated with a relatively thick diffusion-limiting membrane that requires 30–60 minutes to equilibrate after insertion. Persperion's coating is re-engineered for the ultra-small biofluid volumes of fingertip sweat, enabling a usable reading in 30 seconds. 

Additionally, the signal is proportional to glucose concentration allowing a straightforward, linear calibration. Each test strip is reusable for approximately 30 measurements, or roughly a week of typical diabetic monitoring at four measurements per day.

Early feasibility data are encouraging: initial trials have demonstrated a mean absolute relative difference (MARD) that compares favorably to products on the market. Additional pending validation data from larger clinical studies will confirm accuracy, user-to-user variability, and performance under real-world conditions. 

Challenges: Funding, Manufacturing, and the Long Road to FDA

Yin is direct about current challenges: fundraising in the current environment is a significant pressure. Medical device investment has cooled considerably relative to AI and software, and the capital requirements for reaching FDA clearance are substantial. As a result, Persperion is operating with much tighter resources and needs to hit defined milestones to attract the next funding round.

Manufacturing is the second major hurdle. Moving from a research lab to reproducible, high-yield production introduces variables that simply did not exist at small scale. Optimizing these procedures takes longer and costs more than anticipated, and it is work that cannot be shortcut. "People underestimate the level of complexity to do what we're doing," Yin said.

Over the next year, the team is focused on locking in manufacturing processes, validating the device in trials with people with diabetes, and generating the quality of clinical data that will satisfy both investors and regulators. Persperion has multiple patent families covering sensor chemistry and design, which provides some IP foundation for the commercial strategy.

Analysis meter (image courtesy of Persperion)

A Platform, Not Just a Product

Glucose is the first target, but Yin is clear that the company views fingertip sweat sensing as a platform. The same fundamental approach can detect ketone bodies, uric acid (relevant for gout), lactate, creatinine, urea, vitamins, cortisol, and other metabolites — several of which have already been demonstrated in the academic literature from Prof. Wang's group. Future research will determine whether these other analytes will make for commercially viable targets.

The longer-term vision is more sweeping. The bigger picture is beyond diabetic care, and focuses on overall metabolic health. Yin envisions a future where a comprehensive metabolic panel — glucose, uric acid, ketones, creatinine, and more — is accessible through semi-continuous, low-cost touch-based monitoring throughout the day. Rather than relying on indirect proxies like heart rate or blood pressure, patients and clinicians would have direct, quantitative visibility into biochemical health status. "You can get direct feedback on how healthy you are," he said. "A direct view of biomarker could let you better take care of yourself."

Learn more about Persperion Diagnostics and their technology at persperiontech.com.